BioCentury
ARTICLE | Clinical News

Tafluprost regulatory update

November 14, 2011 8:00 AM UTC

Merck received a complete response letter from FDA for an NDA for tafluprost to treat elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The company, which did not disclose details of the letter, said it plans to discuss it with FDA. Tafluprost is a preservative-free, synthetic analog of prostaglandin F2 alpha. ...